Related Experiment Video
Updated: Nov 23, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.5K
The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy
Robert J Hamilton1, Keyue Ding2, Juanita M Crook3
1Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
European Urology
|January 4, 2021
Summary
Statin use in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PCa) was linked to better survival rates. This study suggests statins may improve overall and PCa-specific mortality in these patients.
Area of Science:
- Oncology
- Cardiovascular Pharmacology
Background:
- Conflicting evidence exists on statin use and prostate cancer (PCa) recurrence.
- Limited studies explore statins in advanced PCa stages, particularly with androgen deprivation therapy (ADT).
Purpose of the Study:
- To analyze the association between statin use and survival outcomes in men initiating ADT.
- To conduct a secondary analysis of a randomized controlled trial (RCT) to investigate this association.
Main Methods:
- A post hoc analysis of an RCT involving 1364 men receiving ADT after radiotherapy.
- Statin use was modeled as a time-dependent covariate, adjusting for age, time from radiotherapy to ADT, baseline PSA, and prior ADT.
- Primary endpoint was overall survival; secondary endpoints included PCa-specific mortality and time to castration resistance.
Main Results:
- Statin users (43%) were younger and less likely to have high baseline PSA.
- Statin use was associated with significantly reduced overall mortality (HR: 0.64; P < 0.001) and PCa-specific mortality (HR: 0.65; P = 0.004).
- A trend towards longer time to castration resistance was observed in statin users (P = 0.15).
Conclusions:
- Statin use is associated with improved overall and PCa-specific survival in men treated with ADT post-radiotherapy.
- Further prospective trials are warranted to confirm these findings and explore statins in men commencing ADT.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
01:26Atherosclerosis III: Management
144
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
144
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
326
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
326
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
81
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
81
01:29Therapeutic Drug Monitoring: Affecting Factors
89
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
89
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
340
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
340